Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA - Marme, F.; Hanusch, C.; Furlanetto, J.; Denkert, C.; Link, T.; Untch, M.; Blohmer, J-U.; Jackisch, C.; Reinisch, M.; Rhiem, K. E.; Schneeweiss, A.; Solbach, C.; et al. (ANNALS OF ONCOLOGY, 2021)
CRIS-Team WoS Importer:2021-10-15